FDA Manufacturing Prescription Safety 
Pharmaceutical Technology
MAY 31, 2023
The US Food and Drug Administration (FDA) has proposed a new model for prescription medication guides for brand name and generic drugs, to increase accessibility and reduce medication nonadherence. The FDA said that the proposed revamp should help limit preventable adverse drug reactions and improve health outcomes.
World of DTC Marketing
APRIL 12, 2021
We need a 21st-century approach that puts patient safety first. The US Food and Drug Administration (FDA) believes the adulteration of heparin was an economically motivated act—a clear breach of the US pharmaceutical supply chain. In other words, money over safety. Can patients really be confident in pharma supply chains?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PM360
MAY 25, 2023
The new Food and Drug Administration (FDA)’s Decentralized Clinical Trial Draft Guidance issued May 1 st has started to outline guidelines for increased oversight and planning while simultaneously supporting broader DCT adoption. The guidance document is short at 19 pages, and by design not prescriptive. home health visits).
Pharmaceutical Technology
OCTOBER 25, 2022
Understanding both the significant competitive advantages that FDC products can offer, and the difficulties and potential pitfalls associated with development and manufacturing of FDC drugs in oral solid dosage forms is a critical first step for companies exploring this approach. Pharmaceutical companies – and the FDA – are embracing FDCs.
Legacy MEDSearch
JUNE 30, 2023
Food and Drug Administration (“FDA”) for Cresilon Hemostatic Gel (“CHG ”). This marks Cresilon’s first FDA clearance for human use, validating its revolutionary hemostatic gel technology and the company’s global mission to transform wound care. .” CHG is for prescription use only.
European Pharmaceutical Review
NOVEMBER 15, 2022
As ISPE GAMP 5 Second Edition notes in the preface “Operating in a highly regulated industry may lead practitioners to apply prescriptive and rigid compliance-based approaches that are not commensurate with and not effective in managing any actual risk to the product and the patient.” Takeaways from ISPE’s GAMP 5 Second Edition update.
European Pharmaceutical Review
NOVEMBER 8, 2022
In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. Citizen Petitions before the FDA. Senate Bill 562 (S.
Expert insights. Personalized for you.
52 
Let's personalize your content